Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Q4 upgrade: Why the AVITA (ASX:AVH) share price is soaring

The AVITA Medical Inc (ASX:AVH) share price is soaring today, up 9%, after upgrading its FY21 fourth quarter expectations.

The AVITA Medical Inc (ASX: AVH) share price is soaring today, up 9%, after upgrading its FY21 fourth quarter expectations.

AVITA is a regenerative medicine company that is developing and commercialising a technology platform that enables point of care autologous skin restoration for multiple unmet needs.

The company announced its unaudited FY21 fourth quarter numbers today.

AVITA Q4 success

In the FY21 fourth quarter, AVITA Medical has to date seen total revenue in excess of its guidance range of $8.2 million to $8.6 million.

Based on the strength of both RECELL commercial revenue and BARDA related revenue, the company is raising its fourth quarter guidance to be in the range of $9.5 million to $9.7 million, consisting of $6 million to $6.2 million of RECELL commercial revenue and $3.5 million of RECELL revenue associated BARDA.

BARDA is the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority within the Office of the Assistance Secretary for Preparedness and Response.

The revised RECELL commercial revenue guidance reflects a 55% to 60% increase over the prior comparable period, and a 30% to 34% increase compared to the third quarter of FY21.

Management comments

AVITA Medical CEO Dr Mike Perry said: “As people begin to return to normal activities after the confines of the COVID-19 pandemic, we have seen an increase in burn accidents requiring treatment with the RECELL System in burn centres across the country.”

Things are looking up for the AVITA share price

The AVITA share price had gone up more than 10% since the release of the news that the US Food and Drug Administration (FDA) has approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes and acute full-thickness thermal burn wounds for both pediatric and adult patients.

RECELL is now indicated to treat full-thickness thermal burns in patients 1-month of age and older. This has removed the prior limitation of use in patients younger than 18 years of age. In addition, the indication now includes treatment for full-thickness thermal burns that extend beyond 50% total body surface area (TBSA).

Combined with this improved guidance, it looks like June 2021 is going to be a month of good news.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content